In this review:
This review discusses evidence in support of the use of sacubitril/valsartan (Entresto®) for the treatment of heart failure in hospitalised patients. It presents results and key sub-analyses of the PIONEER-HF and TRANSITION trials in stabilised patients with acute decompensated heart failure, as well as recently released consensus statements from the American College of Cardiology and the Heart Failure Association of the European Society of Cardiology regarding the in-hospital use of sacubitril/valsartan in stabilised patients with heart failure. Real-world studies of sacubitril/valsartan in hospitalised patients are also reviewed, as well as practical considerations for in-hospital initiation of sacubitril/valsartan. This review is sponsored by an educational grant from Novartis (NZ) Ltd.
Please login below to download this issue (PDF)